IPHARMA obtained an approval to conduct the clinical trial of a drug for post-Covid-19 rehabilitatio
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug Treamid.
The investigational drug developer is PHARMENTERPRISES LLC.
Protocol № COVID-TRE-03 "A multicenter randomized double-blind placebo-controlled pilot studyto assess efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia".
The purpose is to assess efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia.
The study will be conducted in 12 clinical sites.